Research ExplorerPublicationsIncidence of subsequent malignancies after total body irradi...

Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial

Standard

Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial. / Eichinger, Anna; Poetschger, Ulrike; Glogova, Evgenia; Bader, Peter; Basu, Oliver; Beier, Rita; Burkhardt, Birgit; Classen, Carl-Friedrich; Claviez, Alexander; Corbacioglu, Selim; Deubzer, Hedwig E; Greil, Johann; Gruhn, Bernd; Güngör, Tayfun; Kafa, Kinan; Kühl, Jörn-Sven; Lang, Peter; Lange, Bjoern Soenke; Meisel, Roland; Müller, Ingo; Sauer, Martin G; Schlegel, Paul-Gerhardt; Schulz, Ansgar; Stachel, Daniel; Strahm, Brigitte; Wawer, Angela; Peters, Christina; Albert, Michael H.

In: LEUKEMIA, Vol. 36, No. 11, 11.2022, p. 2567-2576.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Eichinger, A, Poetschger, U, Glogova, E, Bader, P, Basu, O, Beier, R, Burkhardt, B, Classen, C-F, Claviez, A, Corbacioglu, S, Deubzer, HE, Greil, J, Gruhn, B, Güngör, T, Kafa, K, Kühl, J-S, Lang, P, Lange, BS, Meisel, R, Müller, I, Sauer, MG, Schlegel, P-G, Schulz, A, Stachel, D, Strahm, B, Wawer, A, Peters, C & Albert, MH 2022, 'Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial', LEUKEMIA, vol. 36, no. 11, pp. 2567-2576. https://doi.org/10.1038/s41375-022-01693-z

APA

Eichinger, A., Poetschger, U., Glogova, E., Bader, P., Basu, O., Beier, R., Burkhardt, B., Classen, C-F., Claviez, A., Corbacioglu, S., Deubzer, H. E., Greil, J., Gruhn, B., Güngör, T., Kafa, K., Kühl, J-S., Lang, P., Lange, B. S., Meisel, R., ... Albert, M. H. (2022). Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial. LEUKEMIA, 36(11), 2567-2576. https://doi.org/10.1038/s41375-022-01693-z

Vancouver

Eichinger A, Poetschger U, Glogova E, Bader P, Basu O, Beier R et al. Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial. LEUKEMIA. 2022 Nov;36(11):2567-2576. https://doi.org/10.1038/s41375-022-01693-z

Bibtex

@article{6edd2fed0794460d8b2d08e4ce82396a,
title = "Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial",
abstract = "Total body irradiation (TBI)-based conditioning is associated with superior leukemia-free survival in children with ALL undergoing HSCT. However, the risk for subsequent malignant neoplasms (SMN) remains a significant concern. We analyzed 705 pediatric patients enrolled in the prospective ALL-SCT-BFM-2003 trial and its subsequent registry. Patients >2 years received conditioning with TBI 12 Gy/etoposide (n = 558) and children ≤2 years of age or with contraindications for TBI received busulfan/cyclophosphamide/etoposide (n = 110). The 5- and 10-year cumulative incidence of SMN was 0.02 ± 0.01 and 0.13 ± 0.03, respectively. In total, 39 SMN (34 solid tumors, 5 MDS/AML) were diagnosed in 33 patients at a median of 5.8 years (1.7-13.4), exclusively in the TBI group. Of 33 affected patients, 21 (64%) are alive at a median follow-up of 5.1 years (0-9.9) after diagnosis of their first SMN. In univariate analysis, neither age at HSCT, donor type, acute GVHD, chronic GVHD, nor CMV constituted a significant risk factor for SMN. The only significant risk factor was TBI versus non-TBI based conditioning. This analysis confirms and quantifies the increased risk of SMN in children with ALL after conditioning with TBI. Future strategies to avoid TBI will need careful tailoring within prospective, controlled studies to prevent unfavorable outcomes.",
author = "Anna Eichinger and Ulrike Poetschger and Evgenia Glogova and Peter Bader and Oliver Basu and Rita Beier and Birgit Burkhardt and Carl-Friedrich Classen and Alexander Claviez and Selim Corbacioglu and Deubzer, {Hedwig E} and Johann Greil and Bernd Gruhn and Tayfun G{\"u}ng{\"o}r and Kinan Kafa and J{\"o}rn-Sven K{\"u}hl and Peter Lang and Lange, {Bjoern Soenke} and Roland Meisel and Ingo M{\"u}ller and Sauer, {Martin G} and Paul-Gerhardt Schlegel and Ansgar Schulz and Daniel Stachel and Brigitte Strahm and Angela Wawer and Christina Peters and Albert, {Michael H}",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = nov,
doi = "10.1038/s41375-022-01693-z",
language = "English",
volume = "36",
pages = "2567--2576",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "11",

}

RIS

TY - JOUR

T1 - Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial

AU - Eichinger, Anna

AU - Poetschger, Ulrike

AU - Glogova, Evgenia

AU - Bader, Peter

AU - Basu, Oliver

AU - Beier, Rita

AU - Burkhardt, Birgit

AU - Classen, Carl-Friedrich

AU - Claviez, Alexander

AU - Corbacioglu, Selim

AU - Deubzer, Hedwig E

AU - Greil, Johann

AU - Gruhn, Bernd

AU - Güngör, Tayfun

AU - Kafa, Kinan

AU - Kühl, Jörn-Sven

AU - Lang, Peter

AU - Lange, Bjoern Soenke

AU - Meisel, Roland

AU - Müller, Ingo

AU - Sauer, Martin G

AU - Schlegel, Paul-Gerhardt

AU - Schulz, Ansgar

AU - Stachel, Daniel

AU - Strahm, Brigitte

AU - Wawer, Angela

AU - Peters, Christina

AU - Albert, Michael H

N1 - © 2022. The Author(s).

PY - 2022/11

Y1 - 2022/11

N2 - Total body irradiation (TBI)-based conditioning is associated with superior leukemia-free survival in children with ALL undergoing HSCT. However, the risk for subsequent malignant neoplasms (SMN) remains a significant concern. We analyzed 705 pediatric patients enrolled in the prospective ALL-SCT-BFM-2003 trial and its subsequent registry. Patients >2 years received conditioning with TBI 12 Gy/etoposide (n = 558) and children ≤2 years of age or with contraindications for TBI received busulfan/cyclophosphamide/etoposide (n = 110). The 5- and 10-year cumulative incidence of SMN was 0.02 ± 0.01 and 0.13 ± 0.03, respectively. In total, 39 SMN (34 solid tumors, 5 MDS/AML) were diagnosed in 33 patients at a median of 5.8 years (1.7-13.4), exclusively in the TBI group. Of 33 affected patients, 21 (64%) are alive at a median follow-up of 5.1 years (0-9.9) after diagnosis of their first SMN. In univariate analysis, neither age at HSCT, donor type, acute GVHD, chronic GVHD, nor CMV constituted a significant risk factor for SMN. The only significant risk factor was TBI versus non-TBI based conditioning. This analysis confirms and quantifies the increased risk of SMN in children with ALL after conditioning with TBI. Future strategies to avoid TBI will need careful tailoring within prospective, controlled studies to prevent unfavorable outcomes.

AB - Total body irradiation (TBI)-based conditioning is associated with superior leukemia-free survival in children with ALL undergoing HSCT. However, the risk for subsequent malignant neoplasms (SMN) remains a significant concern. We analyzed 705 pediatric patients enrolled in the prospective ALL-SCT-BFM-2003 trial and its subsequent registry. Patients >2 years received conditioning with TBI 12 Gy/etoposide (n = 558) and children ≤2 years of age or with contraindications for TBI received busulfan/cyclophosphamide/etoposide (n = 110). The 5- and 10-year cumulative incidence of SMN was 0.02 ± 0.01 and 0.13 ± 0.03, respectively. In total, 39 SMN (34 solid tumors, 5 MDS/AML) were diagnosed in 33 patients at a median of 5.8 years (1.7-13.4), exclusively in the TBI group. Of 33 affected patients, 21 (64%) are alive at a median follow-up of 5.1 years (0-9.9) after diagnosis of their first SMN. In univariate analysis, neither age at HSCT, donor type, acute GVHD, chronic GVHD, nor CMV constituted a significant risk factor for SMN. The only significant risk factor was TBI versus non-TBI based conditioning. This analysis confirms and quantifies the increased risk of SMN in children with ALL after conditioning with TBI. Future strategies to avoid TBI will need careful tailoring within prospective, controlled studies to prevent unfavorable outcomes.

U2 - 10.1038/s41375-022-01693-z

DO - 10.1038/s41375-022-01693-z

M3 - SCORING: Journal article

C2 - 36097283

VL - 36

SP - 2567

EP - 2576

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 11

ER -